TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops and markets Pusintin, a bevacizumab injection for the treatment of non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer; and hepatocellular carcinoma. It also offers Tazian, a temozolomide capsule for the treatment of glioblastoma multiforme or anaplastic astrocytoma; and Megaxia, a megestrol acetate oral suspension for the treatment of anorexia associated with acquired immunode¬ciency syndrome, as well as signi¬cant weight loss of AIDS and cancer patients caused by cachexia. In addition, the company is developing TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD). Further, it develops products under preclinical trials, including TAE020 for acute myeloid leukemia; and TAC020 for the treatment various solid tumors. Additionally, the company engages in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China. Address: No. 120 Changyang Street, Suzhou, China, 215024